Maxime Verhoeven

121 Effectiveness and safety of treat-to-target strategies over 5 years Supplementary Table S2 (continued) Median (IQR) [min to max] change in SvdH scores over 5 years TCZ+ MTX (n=38) TCZ (n=40) MTX (n=34) Strategy comparisons; p-value 3 Total SvdH score 0 (0-0) [0 to 5] 0 (0-2) [0 to 30] 0 (0-4) [0 to 35] TCZ+MTX vs. MTX; 0.16 TCZ vs. MTX; 0.31 TCZ+MTX vs. TCZ; 0.11 Erosion score 0 (0-0) [0 to 3] 0 (0-1) [0 to 17] 0 (0-1) [0 to 35] TCZ+MTX vs. MTX; 0.19 TCZ vs. MTX; 0.79 TCZ+MTX vs. TCZ; 0.06 JSN score 0 (0-0) [0 to 5] 0 (0-1) [0 to 13] 0 (0-2) [0 to 6] TCZ+MTX vs. MTX; 0.12 TCZ vs. MTX; 0.35 TCZ+MTX vs. TCZ; 0.15 Mean difference in HAQ scores between initial treatment strategy groups over 5 years # Period Strategy comparisons Mean difference 95%CI of mean difference Over 5 years TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ - 0.01 - 0.06 0.05 - 0.25 to 0.24 - 0.30 to 0.19 - 0.19 to 0.29 The treatment strategy groups are according to the initial randomization at start of U-Act-Early. All analyses were corrected for centre. Outcomes are based onmixedmodel analyses with random intercept for repeated measurements, and fixed effects for treatment arm, visit-week, interaction visit-week*treatment arm. 1 = Cochran-Mantel-Haenszel test, 2 = linear regression, 3 = van Elteren test, # = no statistically significant differences between the groups, Severe RA= baseline DAS28>5.1. TCZ+MTX= tocilizumab + methotrexate initiation strategy group; TCZ= tocilizumab + placebo-methotrexate initiation strategy group; MTX= methotrexate + placebo-tocilizumab initiation strategy group; 95%CI= 95 percent confidence interval; SR= sustained remission; IQR= interquartile range; sDFR= sustained drug free remission; min= minimum; max= maximum; SvdH= Sharp van der Heijde score; JSN= joint space narrowing. Supplementary Table S3 Effectiveness outcomes over 5 years, results based on data of patients included in the post-trial follow-up non-severe RA subgroup, n=114. Mean difference in DAS28 between initial treatment strategy groups over 5 years # Period Strategy comparison Mean difference 95%CI of mean difference Over 5 years TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ - 0.15 - 0.08 -0.07 - 0.42 to 0.21 - 0.35 to 0.19 - 0.42 to 0.13 Sustained (drug free) remission over 5 years TCZ+ MTX (n=37) TCZ (n=39) MTX (n=38) P-value Number of patients (%) achieving SR at least once 37 (100) 37 (95) 38 (100) 0.14 1 Cumulative duration of SR in weeks, median (IQR) 224 (163-254) 203 (141-232) 182 (142-205) <0.01 2 6